Navigation Links
Once-a-year Drug Reduces Fractures from Osteoporosis

A treatment for osteoporosis delivered once a year is as effective as current monthly or weekly osteoporosis regimens at reducing the incidence of bone fractures, according to a new study led by a UCSF research team.

Results from a three-year, international study of 7,736 postmenopausal women with osteoporosis are reported in the May 3, 2007 issue of the "New England Journal of Medicine." Study findings also are available online at

The study showed that treatment with zoledronic acid (marketed as Reclast) was very effective in reducing the incidence of all types of fractures in women with postmenopausal osteoporosis, the researchers said. Impact included a 70 percent reduction in the risk of spinal fractures and a 40 percent reduction in the risk of hip fractures. The effect was sustained over three years.

"The reductions in hip and spine fractures were at least as large as those seen with other drugs in this category," said Dennis Black, PhD, a professor of epidemiology and biostatistics in the UCSF School of Medicine, who led the study. "But even more remarkable were the strong, significant and consistent effects across all fracture types."

Reclast is an investigational drug in the bisphosphonate drug category that is being developed by Novartis Pharmaceuticals Corp., a U.S. affiliate of the Swiss-based Novartis AG. It is the only once-yearly bisphosphonate treatment being studied for osteoporosis and is still in the approval process through the Food and Drug Administration.

Three other drugs in the bisphosphonate family (marketed as Fosamax, Actonel and Boniva) are currently available and most commonly used as a once per week or once per month pill.

"For the first time, women could have the option of being treated once a year for osteoporosis, instead of having to remember to take a weekly pill," Black said. "Adherence to these weekly and monthly regimens is of ten a problem, so an annual treatment means patients are far more likely to actually receive valuable protection against potentially devastating fractures."

Postmenopausal osteoporosis affects millions of women worldwide, Black said, including more than 50 million women in the United States, Europe and Japan combined. Half of those women over age 50 will suffer from an osteoporotic fracture in their lifetime and, of women over age 65 who fracture a hip, 21 percent will die within one year as a result of poor underlying health status, in addition to the acute effects of the fracture.

The study, formally called Health Outcomes and Reduced Incidence with Zoledronic acid Pivotal Fracture Trial, known as HORIZON, was a multinational, randomized, placebo-controlled trial. It evaluated the potential of using a once-yearly infusion of 5 mg of zoledronic acid to decrease the risk of vertebral and hip fractures in postmenopausal women with osteoporosis.

The study also closely examined and put to rest several questions of other side effects of zoledronic acid, such as the renal damage and bone deterioration that has been seen at much larger doses in oncology treatments. The HORIZON study showed no such findings at the lower dose required for osteoporosis treatments.

The study did observe a small increase in the incidence of atrial fibrillation in patients who received zoledronic acid (1.3 percent for zoledronic acid versus 0.5 percent for placebo). Atrial fibrillation is a condition of abnormal heart rhythms, which is one risk factor for stroke.

"The observed increase in atrial fibrillation was very small less than one in 100 patients so it needs to be weighed against the reduction in fracture risk," Black said. This increase was unexpected and has not been seen in other studies of zoledronic acid. He recommends that it be further examined.

The May 3 issue of "NEJM" also includes a letter reg arding a separate study on a different drug in the bisphosphonate family, which showed a similar, but not statistically significant, increased risk of atrial fibrillation. That study also was conducted by the UCSF group.

As was expected, there was also a slight increase in minor side effects, such as fever or muscle pain. Those effects were seen within three days of the first infusion but not after the second or third.


Related medicine news :

1. Drug Reduces Risk of Clogged Arteries, Veins
2. Sunshine Reduces MS Risk
3. Estrogen in Food Reduces Cancer Risk
4. Dental Procedure Reduces Preterm Births
5. Vaccine Reduces antibiotic-resistant infections in Children
6. Eating Fiber Reduces The Risk Of Heart Disease
7. Higher Statin Dose Safely Reduces Stroke and Cardiac Arrest
8. Anti-tobacco Advertising Can Reduces smoking Among Teens
9. Eating Fish Reduces Heart Disease
10. Co-trimoxazole Use Reduces Childhood AIDS –Related Death
11. NSAIDS, Reduces The Risk Of Oral Cancer But Causes Heart Attacks
Post Your Comments:

(Date:10/13/2017)... ... October 13, 2017 , ... As health professionals work to ... “patient engagement.” The patient is doing more than filling out a survey; in many ... is an increasing emphasis in health care and research on the importance of active ...
(Date:10/13/2017)... ... October 13, 2017 , ... PurhealthRX , a leading Health and Nutrition ... the Purzorb™process to full spectrum CBD oil will revolutionize the rapidly growing CBD market ... can be easily incorporated into liquid products, while reducing costs to end users. , ...
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... Many families ... However, many long-term care insurance companies have a waiver for care if the client ... elimination period, when the family pays for care, is often waived, so the benefits ...
(Date:10/13/2017)... Abilene, Texas (PRWEB) , ... October 13, 2017 , ... ... publication this week that explains one of the most popular and least understood books ... seems like cryptic and puzzling descriptions that have baffled scholars for centuries. Many have ...
(Date:10/13/2017)... , ... October 13, 2017 , ... “America On The ... identity. “America On The Brink” is the creation of published author, William Nowers. ... great-grandchildren. As a WWII veteran, he spent thirty years in the Navy. ...
Breaking Medicine News(10 mins):
(Date:9/25/2017)... , Sept. 25, 2017   Montrium , ... File solutions, today—from the IQPC Trial Master Files ... , NL)—announced that EastHORN Clinical Services has selected ... programs and TMF management. EastHORN, a leading European ... platform to increase transparency to enable greater collaboration ...
(Date:9/19/2017)... ANN ARBOR, Mich. , Sept. 19, 2017 HistoSonics, Inc., a venture-backed medical ... the precise destruction of targeted tissues, announced three leadership team developments today:   ... Josh Stopek, PhD ... ... Veteran medical device executive ...
(Date:9/12/2017)... NEW YORK , Sept. 12, 2017   EcoVadis , the ... chains, has published the first annual edition of its Global CSR Risk ... 20,400 companies evaluated by EcoVadis, based on Scorecard Ratings that analyzed nearly ... ... Performance Index ...
Breaking Medicine Technology: